Benitec Biopharma(BNTC) Plunges 8.10% on Earnings Concerns

Benitec Biopharma(BNTC) shares plummeted 8.10% today, marking the third consecutive day of decline, with a cumulative drop of 24.18% over the past three days. The stock price hit its lowest level since April 2025, experiencing an intraday decline of 11.66%.

The strategy of buying BNTC shares after they reached a recent low and holding for 1 week showed poor performance over the past 5 years. The annualized return was -14.5%, significantly underperforming the market. This indicates that this strategy was not profitable, and investors may have incurred losses rather than gains.

Benitec Biopharma's stock is currently trading at $13.16, which is below its 50-day moving average of $14.44 but above its 200-day moving average of $11.99. This indicates recent fluctuations in stock price performance relative to short-term and long-term trends.

Earnings for Benitec Biopharma are anticipated to decrease in the coming year, from ($1.48) to ($2.31) per share. This expectation of declining earnings could impact investor sentiment and stock valuation.

On May 15, 2025, JMP Securities Analyst Silvan Tuerkcan reiterated a "Market Outperform" rating for Benitec Biopharma, despite a recent stock price of $12.35, marking a 6.2% drop. Analyst recommendations can influence investor decisions and stock movement.